You are here: Industry Insights > Allergan

News List

Amgen and Allergan win FDA nod for biosimilar of Avastin, Roche's $3B seller fiercepharma
September 15, 2017
The FDA has ushered in a new era in lower cost cancer medicines with its approval of Amgen’s and Allergan's Mvasi, a biosimilar of Roche’s blockbuster drug Avastin.
New migraine results for both Allergan and Novartis pharmatimes
September 12, 2017
Allergan has announced new head-to-head data from an open label study in chronic migraine demonstrating that Botox (onabotulinumtoxinA) had a more favourable tolerability profile than Topamax (topiramate).
Final NHS green light for Allergan’s IBS-D drug pharmatimes
September 01, 2017
Allergan’s Truberzi has become the first treatment for irritable bowel syndrome with diarrhoea (IBS-D) to be reviewed and recommended by the National Institute for Health and Care Excellence for use on the NHS in England and Wales.
Allergan hits its already battered Irvine site with another round of job cuts fiercepharma
August 30, 2017
Allergan's Irvine campus was the site of hundreds of job cuts in 2014 and 2015.
Allergan heads to federal court to defend Restasis against early generic rivals fiercepharma
August 30, 2017
Allergan is facing off in federal court against generics companies seeking to market copies of Restasis, whose sales slipped in the second quarter.
Paratek rising fast after Bloomberg says it is up for sale fiercebiotech
August 24, 2017
CEO Michael Bigham has said omadacycline has blockbuster potential.
Has the Brent Saunders price-hike limit become a de facto pharma rule? fiercepharma
August 15, 2017
Allergan CEO Brent Saunders' pledge to limit price hikes has distinctly affected the industry's pricing practices, data from Bernstein show.
Payer coverage in place, Allergan gets ready to ramp Rhofade promotion fiercepharma
August 10, 2017
Allergan commercial chief Bill Meury says the company is aiming to turn Rhofade into a multihundred-million-dollar dermatology product.
Botox, fillers steal the show as Allergan posts Q2 beats fiercepharma
August 07, 2017
Allergan’s catching a break this year, and it’s one that Thursday allowed it to hike its guidance for 2017.
Amgen, Allergan’s Herceptin biosimilar filed in the US pharmatimes
August 02, 2017
US biotech giant Amgen and Dublin, Ireland-based Allergan have now filed ABP 980 - a biosimilar version of Roche’s blockbuster biologic trastuzumab - with the US Food and Drug Administration.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page